Trials / Conditions / Relapsed B-cell Acute Lymphoblastic Leukemia

Relapsed B-cell Acute Lymphoblastic Leukemia

7 registered clinical trials studyying Relapsed B-cell Acute Lymphoblastic Leukemia — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL NCT06179524	Beijing Yongtai Ruike Biotechnology Company Ltd	Phase 2
Terminated	Blinatumomab Bridging Therapy for BALL NCT04556084	Michael Burke	Phase 2
Unknown	A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects NCT03156101	Shenzhen BinDeBio Ltd.	Phase 1 / Phase 2
Completed	Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia NCT02808442	Institut de Recherches Internationales Servier	Phase 1
Withdrawn	Study of Efficacy and Safety of CTL019 in Adult ALL Patients NCT02167360	Abramson Cancer Center at Penn Medicine	Phase 2
Completed	Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients NCT02228096	Novartis Pharmaceuticals	Phase 2
Active Not Recruiting	T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients W NCT01860937	Memorial Sloan Kettering Cancer Center	Phase 1